Director Michael J. Purcell filed a Form 4 with the SEC on October 27, 2026, disclosing the acquisition of 510,000 stock options in Hepion Pharmaceuticals, Inc. (OTC:HEPA) on October 23, 2026.

Key Highlights

  • Transaction date: October 23, 2026, with 510,000 stock options acquired (transaction code A).
  • Exercise price: $0.14 per share, with an expiration date of October 23, 2036.
  • Vesting schedule: According to the filing, 42,500 options vest in equal amounts monthly over 12 months from the date of grant.
  • Price paid: The filing states the price of the derivative security as $0, indicating no cash consideration paid at grant.
  • Resulting holdings: Following the transaction, Purcell beneficially owns 809,000 stock options, held directly.
  • Underlying security: Each option corresponds to common stock of Hepion Pharmaceuticals, Inc.

Purcell's October 2026 Stock Option Grant at Hepion Pharmaceuticals

According to the Form 4 filed on October 27, 2026, Michael J. Purcell, a director of Hepion Pharmaceuticals, Inc. (OTC:HEPA), was granted 510,000 stock options on October 23, 2026. The filing reports an exercise price of $0.14 per share and an expiration date of October 23, 2036. The price of the derivative security at grant is listed as $0, meaning no cash consideration was paid by Purcell at the time of the award.

The filing discloses that 42,500 options vest in equal amounts monthly over 12 months from the date of grant. The options are exercisable into common stock of Hepion Pharmaceuticals, with the underlying share count matching the 510,000 options granted. Purcell holds these options directly, as indicated in the ownership form column of Table II.

Following the reported transaction, Purcell's total beneficial ownership of stock options stands at 809,000, according to the filing. The Form 4 was signed by Michael Purcell and filed on October 27, 2026. No non-derivative securities transactions were reported in Table I of the filing.

What Was Disclosed

The filing reports the grant of 510,000 stock options to director Michael J. Purcell on October 23, 2026, at an exercise price of $0.14 per share, expiring October 23, 2036, with a monthly vesting schedule over 12 months, resulting in total beneficial ownership of 809,000 options.